Since the previous evidence showed that gemcitabine, a chemotherapeutic agent, induced MUC1 upregulation in primary intrahepatic cholangiocarcinoma cells from patients51, the combination of anti-MUC1-CAR T cells with gemcitabine may be a potential treatment in patients with CCA. Here, MUC1 is linked to cholangiocarcinoma.